Thalidomide-NH-C6-NH2 TFA
Modify Date: 2024-01-10 20:52:29
Thalidomide-NH-C6-NH2 TFA structure
|
Common Name | Thalidomide-NH-C6-NH2 TFA | ||
|---|---|---|---|---|
| CAS Number | 2093386-51-5 | Molecular Weight | 486.44 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H25F3N4O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Thalidomide-NH-C6-NH2 TFAThalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. |
| Name | Thalidomide-NH-C6-NH2 TFA |
|---|
| Description | Thalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. |
|---|---|
| Related Catalog | |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. |
| References |
| Molecular Formula | C21H25F3N4O6 |
|---|---|
| Molecular Weight | 486.44 |
| Hazard Codes | Xi |
|---|